1. Background
2. Objectives
3. Methods
3.1. Biochemical Identification
3.2. Antibiotic Susceptibility Testing
3.3. Genotypic Detection of Virulence and Antibiotic Resistant Genes
| Gene | Primer Sequence (5´ - 3´) | PCR Product, bp | Annealing Tm | Reference |
|---|---|---|---|---|
| vanA | 5´-GGGAAAACGACAATTGC-3´ | 732 | 54 | (12) |
| 5´-GTACAATGCGGCCGTTA-3´ | ||||
| vanB | 5´-ATGGGAAGCCGATAGTC-3´ | 635 | 58 | (12) |
| 5´-GATTTCGTTCTTCGACC-3´ | ||||
| aac6-aph2 | 5′- CTGATGAGATAGTCTATGGTATGGATC - 3′ | 375 | 61 | (11) |
| 5′ - GCCACACTATCATAACCACTACCG - 3′ | ||||
| ermB | 5′ - CGACGAAACTGGCTAAAATAAGTAAAC - 3′ | 408 | 52 | (11) |
| 5′- GAGGTATGGCGGGTAAGTTTTATTAAG - 3′ | ||||
| tetM | 5′- GGACAAAGGTACAACGAGGAC - 3′ | 445 | 55 | (11) |
| 5′- GGTCATCGTTTCCCTCTATTACC -3′ | ||||
| asaI | 5′-GCACGCTATTACCAACTATGA-3′ | 375 | 56 | (13) |
| 5′-TAAGAAAGAACATCACCACGA-3′ | ||||
| ace | 5′-GGAATGACCGAGAACGATGGC-3′ | 616 | 56 | (12) |
| 5′-GCTTGATGTTGGCCTGCTTCCG-3′ | ||||
| acm | 5′-GGCTAGTCGTTACAAATGAG-3′ | 655 | 56 | (14) |
| 5′-ATTTTATTCTTTTGATTTCAGTC-3′ | ||||
| gelE | 5′-ACCCCGTATCATTGGTTT-3′ | 419 | 56 | (15) |
| 5′-ACGCATTGCTTTTCCATC-3′ | ||||
| esp | 5′-CGATAAAGAAGAGAGCGGAG-3′ | 539 | 56 | (13) |
| 5′-GCAAACTCTACATCCACGTC-3′ | ||||
| hyl | 5′-ACAGAAGAGCTGCAGGAAATG-3′ | 276 | 56 | (13) |
| 5′-GACTGACGTCCAAGTTCCCAA-3′ | ||||
| cylA | 5′ -ACTCGGGGATTGATAGGC-3′ | 688 | 56 | (13) |
| 5′-GCTGCTAAAGCTGCGCTT-3′ | ||||
| E. faecalisddl | 5´-ATCAAGTACAGTTAGTCTTTATTAG-3´ | 941 | 49 | (12) |
| 5´-ACGATTCAAAGCTAACTGAATCAGT-3´ | ||||
| E. faeciumddl | 5´-TTGAGGCAGACCAGATTGACG-3´ | 658 | 50 | (12) |
| 5´-TATGACAGCGACTCCGATTCC-3´ |
3.4. Statistical Analysis
4. Results
4.1. Bacterial Strain
4.2. Phenotypic and Genotypic Antibiotic Susceptibility Pattern
| Species | |||
|---|---|---|---|
| Antibiotic | Enterococcus faecalis Isolates (n = 63) | Enterococcus faecium Isolates (n = 22) | Total Isolates (N = 85) |
| Vancomycinc | 6 (9.5) | 12 (54.5) | 18 (21.17) |
| Teicoplanin | 6 (9.5) | 12 (54.5) | 18 (21.17) |
| Imipenem | 4 (7.14) | 12 (54.5) | 16 (18.82) |
| Linezolid | 0 | 2 (9.09) | 2 (2.35) |
| Nitrofurantoin | 5 (7.93) | 12 (54.5) | 17 (20) |
| Ciprofloxacin | 8 (12.69) | 11 (50) | 19 (31.85) |
| Gentamicin 120c | 10 (15.87) | 12 (54.5) | 23 (27.05) |
| Fosfomycin | 0 | 7 (38.1) | 7 (8.23) |
| Quinupristin/Dalfopristin | 0 | 4 (18.1) | 4 (4.7) |
| Chloramphenicol | 0 | 6 (27.2) | 19 (16.81) |
| Tetracyclinec | 39 (61.9) | 17 (77.2) | 56 (65.88) |
| Erythromycinc | 20 (31.74) | 14 (63.6) | 34 (40) |
| Ampicillin | 8 (12.6) | 12 (54.5) | 20 (23.52) |
| Piperacillin | 5 (7.93) | 10 (45.4) | 18 (21.17) |
aValues are expressed as No. (%).
bThe table just illustrated a high frequency of antibiotics resistant in E. faecium more than E. faecalis by disk diffusion method (P < 0.05).
cThese antibiotics were evaluated both phenotypically and genotypically.
4.3. Virulence Determinant Characterization
| Species | Source | Hospital Ward | Antibiotic Resistance Genes | MICv | Virulence Factors Genes | Other Antibiotics Resistance (Phenotypic) |
|---|---|---|---|---|---|---|
| E. faecalis | Urine | ICU- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa1- cylA | Am-Ni-Im-Pi-Cip |
| E. faecalis | Urine | CCU- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB,t etM | ≥ 256 | asa I | Am-Im-Pi-Cip |
| E. faecalis | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I-gelE | Am-Im-Cip |
| E. faecalis | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | cylA | Ni-Pi-Cip |
| E. faecalis | Urine | pediatrics- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | gelE-esp | Am-Ni-Pi-Cip |
| E. faecalis | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I-gelE | Im-Pi-Cip |
| E. faecium | Blood | ICU- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | gelE | Ni-Im-Chl-Syn |
| E. faecium | Urine | ICU- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I- esp | Am-Ni-Pi-Cip |
| E. faecium | Urine | ICU- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I- esp | Am-Ni-Im-Pi-Cip-Chl |
| E. faecium | Urine | ICU - m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I- esp | Am-Ni-Im-Pi-Cip-Chl |
| E. faecium | Urine | ICU - m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I- esp | Am-Im-Cip-Syn |
| E. faecium | Urine | ICU- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I- esp | Am-Im-Pi-Cip-Chl-Li-Fo |
| E. faecium | Urine | pediatrics- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | gelE | Ni-Im-Pi-Cip |
| E. faecium | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | esp-gelE | Am-Im-Pi-Cip |
| E. faecium | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB,tetM | ≥ 256 | esp-gelE | Am-Im-Pi-Cip |
| E. faecium | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I-esp | Am-Ni-Im-Pi-Cip |
| E. faecium | Urine | pediatrics- f | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | asa I | Cip-Syn |
| E. faecium | Urine | Transplantation- m | vanA, aac (6)-Ie-aph (2)-Ia, ermB, tetM | ≥ 256 | None | Im-Pi-Cip-Syn-Li-Fo |
Abbreviations: M, male; F, female; Am, Ampicilin; Ni, Nitrofurantoin; Im, Imipenem; Chl, Chloramphenicol; Syn, Quinupristin/Dalfopristin; Cip, Ciprofloxacin; Pi, Piperacillin; Li, Linezolid; Fo, fosfomycin; MICv, the strains associated with high level vancomycin resistance.

